BOSTON--(BUSINESS WIRE)--“Global HIV, viral hepatitis epidemics and sexually transmitted infections (STIs) continue to pose significant public health challenges, causing 2.5 million deaths each year,” according to a new WHO report. The report found four curable STIs -- chlamydia, gonorrhea, syphilis and trichomoniasis -- are responsible for more than 1 million infections daily among adults between ages 15 and 49, and binx health is continuing its strategy of expanding access to rapid onsite testing for chlamydia and gonorrhea, which are the most common reportable STI infections in the USA..

波士顿--（商业新闻短讯）--“根据世卫组织的一份新报告，全球艾滋病毒、病毒性肝炎流行病和性传播感染（STI）继续对公共卫生构成重大挑战，每年造成250万人死亡。”。该报告发现，衣原体、淋病、梅毒和滴虫病这四种可治愈的性传播感染在15至49岁的成年人中每天造成100多万例感染，binx health正在继续其扩大衣原体和淋病快速现场检测的策略，这是美国最常见的可报告性传播感染。。

“There is a pressing need for affordable rapid multiplex platforms that can simultaneously diagnose multiple pathogens, and for reliable point-of-care technologies appropriate for use in health care settings with no or limited access to a laboratory,” said the WHO.

世卫组织表示：“迫切需要能够同时诊断多种病原体的负担得起的快速多重平台，以及适合在没有或限制进入实验室的医疗保健环境中使用的可靠的即时护理技术。”。

“We’re excited by the adds to our commercial team and bringing on our fifth distribution partner in the coming days,” said Jeffrey Luber, binx health CEO. “This will bring our commercial footprint nationally to well over 1,200 as we continue to see clinics convert from multi-day wait times to rapid answers onsite for both male and female populations through binx.

binx health首席执行官杰弗里·卢伯（JeffreyLuber）表示：“我们对加入我们的商业团队以及在未来几天引入我们的第五个分销合作伙伴感到兴奋。”。“这将使我们在全国的商业足迹超过1200个，因为我们继续看到诊所通过binx从多日等待时间转变为现场快速回答男性和女性人群。

The future is point-of-care and we’re excited to be leading the charge in sexual health.”.

未来是护理的重点，我们很高兴能够在性健康方面发挥领导作用。”。

The binx® io molecular point-of-care system continues to be the only FDA-cleared, CLIA-waived molecular testing platform that can test both males and females for chlamydia and gonorrhea in about thirty minutes at levels of accuracy comparable to central-laboratory testing, consistent with the WHO’s call-to-action.

binx®io分子点护理系统仍然是唯一一个FDA批准、CLIA豁免的分子检测平台，可以在大约30分钟内检测男性和女性的衣原体和淋病，其准确度与中央实验室检测相当，符合WHO的行动呼吁。

Using urine specimens from males and clinician- or self-collected vaginal swabs from females, the binx platform is seeing broad adoption across market verticals and clinic types. Unlike traditional test workflows, results are available with binx in minutes rather than days, enabling clinicians to have conversations with patients who test positive while they are still in the clinic—preventing loss to follow up and empiric antibiotic prescribing..

binx平台使用男性尿液样本和女性临床医生或自行采集的阴道拭子，在市场垂直领域和临床类型中得到广泛采用。与传统的测试工作流程不同，binx可以在几分钟而不是几天内获得结果，使临床医生能够与仍在诊所的测试呈阳性的患者进行对话，以防止失去随访和经验性抗生素处方。。

“A powerful tool in achieving the WHO’s ambitious STI screening goals is to arm our providers with a point-of-care platform that can lead to treatment guidance for all populations coming to us, before the patient leaves our clinic,” said Melissa Reed, CEO of Planned Parenthood Keystone, Warminster PA.

。

“Only binx offers a platform with this ability, furthering WHO’s goal of health equity and inclusion of everyone regardless of gender and sexual orientation. The binx platform’s ability to test both female vaginal swabs and male urine specimens give us this broad ability.”.

“只有binx提供了一个具有这种能力的平台，进一步实现了世卫组织健康公平的目标，让每个人都不分性别和性取向。binx平台测试女性阴道拭子和男性尿液样本的能力为我们提供了这种广泛的能力。”。

The WHO report further emphasized the importance of access to STI testing strategies and strengthening efforts for those at higher risk of infection including sex workers, men who have sex with men, transgender people, adolescents in some settings and pregnant women. Point-of-care platforms that can rapidly test both males and females remain critical in the tool set of clinics when selecting a solution for such broad populations..

世卫组织的报告进一步强调了获得性传播感染检测策略的重要性，并加强了感染风险较高人群的努力，包括性工作者、男男性行为者、变性人、某些环境中的青少年和孕妇。在为如此广泛的人群选择解决方案时，可以快速测试男性和女性的即时护理平台在诊所的工具集中仍然至关重要。。

“Having served in leadership roles with both Thermo Fisher and Abbott Diagnostics, I had the opportunity to see up close the market need for male/female rapid onsite testing that connects to EHR,” said Michael Karsonovich, binx health, Chief Commercial Officer. “I joined binx due to the market need for better solutions as a key driver to stem the tide of infection spread.

binx health首席商务官迈克尔·卡索诺维奇（MichaelKarsonovich）表示：“我曾在赛默飞世尔（Thermo Fisher）和雅培诊断（Abbott Diagnostics）担任领导职务，因此有机会近距离了解市场对连接EHR的男性/女性快速现场检测的需求。”。“我加入binx是因为市场需要更好的解决方案，这是阻止感染蔓延的关键因素。

Given the demand we’re seeing in the market and the strength of our manufacturing and distribution relationships, I’m heartened by the strong role we can play in addressing the concerns recently raised by the WHO.”.

鉴于我们在市场上看到的需求以及我们制造和分销关系的强大，我对我们在解决世界卫生组织最近提出的问题方面可以发挥的强大作用感到鼓舞。”。

With global manufacturing in the US, Europe and APAC, and the relationships binx has built with the best commercial distribution partners in the industry, the company continues to lead the market in scalable, low cost-of-goods solutions for the millions of people who need them. Manufacturing partners including Harmac Medical Products’ Ireland division, which has helped arm binx with strides in capacity and low COGS to meet rising demand..

凭借在美国、欧洲和亚太地区的全球制造业，以及宾克斯与业界最佳商业分销合作伙伴建立的关系，该公司继续领导市场，为数百万需要它们的人提供可扩展、低成本的商品解决方案。制造合作伙伴包括哈马克医疗产品爱尔兰分部，该分部帮助binx在产能和低齿轮方面取得长足进步，以满足不断增长的需求。。

“Our vision at Harmac Medical Products is ‘changing the lives of patients, employees and communities in which we work’. We are thrilled to be working with binx to manufacture a product that upholds these values and has the ability to impact patient outcomes given rising demand,” said John Somers, President and CEO of Harmac Medical Products.

哈马克医疗产品总裁兼首席执行官约翰·萨默斯（JohnSomers）表示：“我们在哈马克医疗产品公司的愿景是‘改变患者、员工和我们工作的社区的生活’。我们很高兴能与binx公司合作，生产出一种支持这些价值观的产品，并且能够在需求不断增长的情况下影响患者的预后。”。

“The ability to partner with binx and advance the manufacture of their critically important product for public health perfectly fits with Harmac’s manufacturing expertise and we look forward to being part of the solution of helping to stem the STI epidemic globally.”.

“与binx合作并推进其至关重要的公共卫生产品制造的能力完全符合Harmac的制造专业知识，我们期待着成为帮助全球遏制性病流行的解决方案的一部分。”。

About binx health

关于binx health

binx health® is a healthcare technology and diagnostics company focused on innovating solutions to improve routine testing and convenience, providing timely results to improve patient care. The binx io point-of-care molecular platform is the first ever FDA-cleared, CLIA-waived point-of-care system for the detection of chlamydia and gonorrhea in both males (urine) and females (vaginal swab) that provides results in about thirty minutes with performance comparable to central labs.

binx health®是一家医疗保健技术和诊断公司，专注于创新解决方案，以改进常规检测和便利性，及时提供结果，改善患者护理。binx io护理点分子平台是有史以来第一个FDA批准的，CLIA放弃的护理点系统，用于检测男性（尿液）和女性（阴道拭子）的衣原体和淋病，可在约30分钟内提供结果，性能与中央实验室相当。

The binx io platform is highly flexible, easy to use, and enables rapid testing and treatment in a single patient visit. For more information, visit https://mybinxhealth.com.

binx io平台非常灵活，易于使用，可以在一次患者就诊中进行快速检测和治疗。有关更多信息，请访问https://mybinxhealth.com.